This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Allegations of Boehringer Ingelheim 'evergreening' patent not a subject for Indian antitrust watchdog

By Freny Patel ( August 24, 2023, 01:24 GMT | Insight) -- Allegations that the German pharma major Boehringer Ingelheim had contravened provisions of India's competition law were dismissed by the antitrust watchdog on Wednesday. The Competition Commission of India dismissed the case of Boehringer Ingelheim allegedly evergreening a patent on grounds that the validity of a patent was not a subject for the authority to investigate for want of "subject matter competence" and given that the issue is pending before competent courts.  Antitrust allegations filed against Boehringer Ingelheim Pharma GmbH & Co by its peer Macleods Pharmaceuticals were dismissed by the Indian watchdog on Wednesday....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login